CONSORT diagram. In the SRs arm, 1 of 5 SRs was chosen before randomization for each patient by the investigator. The safety population included all the patients in the ITT (randomized) population who underwent leukapheresis or received bridging therapy, lymphodepleting chemotherapy, or ide-cel (ide-cel arm) or who received any dose of daratumumab, pomalidomide, lenalidomide, bortezomib, ixazomib, carfilzomib, elotuzumab, or dexamethasone (SRs arm). The treated population included all patients who received the treatment to which they were randomly assigned. Of 254 patients in the ide-cel arm in the ITT population, 249 underwent leukapheresis (safety population), 212 received bridging therapy, 227 received lymphocyte-depleting chemotherapy, and 225 received a single infusion of ide-cel. Five patients in the SRs arm had confirmed PD before treatment crossover to ide-cel was permitted after protocol amendment 2; instead, they received other subsequent antimyeloma therapies. DPd, daratumumab, pomalidomide, and dexamethasone; DVd, daratumumab, bortezomib, and dexamethasone; EPd, elotuzumab, pomalidomide, and dexamethasone; IRd, ixazomib, lenalidomide, and dexamethasone; Kd, carfilzomib and dexamethasone.